摘要
目的:探讨Er:YAG激光治疗女性外阴硬化性苔藓(VLS)的临床疗效及安全性。方法:选取2021年7月至2023年7月在我院妇科门诊就诊并经组织学证实为VLS的80例女性患者,根据患者选择的治疗方式分为两组各40例。试验组采用Er:YAG激光治疗,对照组采用派瑞松乳膏外涂治疗。采用视觉模拟评分方法(VAS)对试验组和对照组治疗前后外阴瘙痒、外阴灼痛、性交疼痛、对生活质量的影响、皮肤弹性、皮肤颜色、病变范围等情况进行评分,对比分析两组的治疗效果。结果:试验组的治疗总有效率为97.5%,高于对照组的70%(P<0.05)。试验组疗程结束后3个月外阴瘙痒、外阴灼痛、性交疼痛、对生活质量的影响、皮肤弹性、皮肤颜色及病变范围评分均显著低于对照组(P<0.05)。结论:Er:YAG激光治疗能够显著改善VLS的症状及体征,提高患者的生活质量,减少疾病复发的风险,且治疗过程中无明显不良反应,可作为VLS患者的一种新的治疗选择。
Objective To investigate the clinical efficacy and safety of Er:YAG laser for the treatment of female vulvar li⁃chen sclerosus(VLS).Methods Eighty female patients diagnosed with VLS in the Department of Obstetrics and Gynecolo⁃gy,Taihe Hospital,Hubei University of Medicine from July 2021 to July 2023 were selected.They were divided into two groups(40 cases each)according to their treatment option.The experimental group received Er:YAG laser treatment,while the control group was treated with topical application of Propionate cream.Visual analogue score(VAS)was used to evaluate the vulvar itching,vulvar burning pain,pain during sexual intercourse,impact on quality of life,skin elasticity,skin color,and lesion extent before and after treatment in both groups.Results The total effective rate of treatment in the experimental group was 97.5%,higher than the 70%in the control group(P<0.05).Additionally,3 months after treat⁃ment,the scores for vulvar itching,vulvar burning pain,pain during sexual intercourse,impact on quality of life,skin e⁃lasticity,skin color,and lesion extent were lower in the experimental group than in the control group(P<0.05).Conclu⁃sion Er:YAG laser significantly improves the signs and symptoms of VLS,enhances the quality of life of patients,and re⁃duces the risk of disease recurrence without causing any obvious adverse reactions.Therefore,it can be considered a new treatment option for VLS patients.
作者
邱又茜
柯玉芳
肖珍迪
黄文广
方彩云
QIU You-xi;KE Yu-fang;XI-AO Zhen-di;HUANG Guang-wen;FANG Cai-yun(Department of Obstetrics and Gynecology,Taihe Hospital,Hubei U-niversity of Medicine,Shiyan,Hubei 442000,China)
出处
《湖北医药学院学报》
CAS
2024年第5期540-545,共6页
Journal of Hubei University of Medicine
基金
十堰市引导性科研项目(编号21Y27)。